<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00956982</url>
  </required_header>
  <id_info>
    <org_study_id>KULDS2009</org_study_id>
    <nct_id>NCT00956982</nct_id>
  </id_info>
  <brief_title>PEG-IFN Plus Ribavirin Combination Therapy for Older Patients</brief_title>
  <official_title>Pegylated Interferon Alpha-2b Plus Ribavirin Combination Treatment for Older Patients With Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyushu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyushu University</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyze the efficacy and safety of a combination therapy of
      pegylated interferon (PEG-IFN) alpha-2b plus ribavirin (RBV) for older Japanese patients
      (≧65years old) infected with hepatitis C virus (HCV) compared with younger patients(&lt; 65
      years old).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>antiviral effect by PEG-IFN alpha-2b plus RBV treatment</measure>
    <time_frame>24-weeks follow-up after the end of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>the tolerance of older patients by PEG-IFN alpha-2b plus RBV treatment</measure>
    <time_frame>during PEG-IFN alpha-2b plus RBV treatment (48 weeks)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1251</enrollment>
  <condition>Hepatitis C Virus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alpha-2b plus ribavirin</intervention_name>
    <description>All patients were treated with a weight-based, 1.5 μg/kg weekly dose of subcutaneous PEG-IFN alpha-2b (PegIntron A, Schering-Plough, Osaka, Japan), in combination with PEG-IFN alpha-2b, RBV (Rebetol; Schering-Plough), which was given orally at a daily dose of 600-1000mg based on bodyweight (600 mg for patients weighing &lt; 60 kg, 800 mg for those weighing 60-80 kg, and 1000 mg for those weighing 80 kg). The length of treatment was 48 weeks for patients with HCV of genotype 1and 24 weeks for patients with genotypes 2, respectively</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A prospective study of 2270 Japanese patients aged 18 years or older treated with
             PEG-IFN alpha-2b plus RBV was done between December 2004 and July 2008.

          -  All positive for both antibody to HCV and HCV-RNA for over six months and were
             enrolled.

        Exclusion Criteria:

          -  Clinical or biochemical evidence of hepatic decompensation.

          -  Advanced cirrhosis identified by large esophageal varices (F2 or F3).

          -  History of gastrointestinal bleeding, ascites, encephalopathy, or hepatocellular
             carcinoma.

          -  Hemoglobin level &lt; 11.5g/L, white blood cell count &lt; 3×10９/Ｌ，and platelet count &lt;
             50×10９/Ｌ.

          -  Concomitant liver disease other than hepatitis C(hepatitis B surface antigen positive
             or HIV positive).

          -  Excessive active alcohol consumption &gt; 60 g/day or drug abuse.

          -  Severe psychiatric disease.

          -  Antiviral or corticosteroid therapy within 12 months prior to the enrollment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Hayashi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of General Medicine, Kyushu University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Hayashi</last_name>
    <phone>+81-92-642-5909</phone>
    <email>hayashij@genmedpr.med.kyushu-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of General Medicine, Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mosaburo Kainuma</last_name>
      <phone>+81-92-642-5909</phone>
      <email>kainuma@genmedpr.med.kyushu-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Jun Hayashi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <lastchanged_date>August 10, 2009</lastchanged_date>
  <firstreceived_date>August 6, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Jun Hayashi</name_title>
    <organization>Department of General Medicine, Kyushu University Hospital</organization>
  </responsible_party>
  <keyword>Hepatitis C Virus Pegylated Interferon Ribavirin Older</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
